BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Casdatifan readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Casdatifan\, from ClinicalTrials.gov esti
 mates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT07000149-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270129
DTEND;VALUE=DATE:20270130
SUMMARY:Casdatifan: Phase 1 readout est. (NCT07000149)
DESCRIPTION:Casdatifan\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStudy:
  A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatif
 an vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCC\nEstimated
  primary completion: 29 January 2027. This is a ClinicalTrials.gov estimat
 e\, not a confirmed readout date\, and it can move.\nDrug page: https://as
 setmemo.bio/drug/casdatifan#upcoming-events\nRegistry record: https://clin
 icaltrials.gov/study/NCT07000149
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07751250-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20270531
DTEND;VALUE=DATE:20270601
SUMMARY:Casdatifan: Phase 1 readout est. (NCT07751250)
DESCRIPTION:Casdatifan\, phase 1.\nStudy: Comparative PK Assessment Study o
 f Casdatifan in Moderate Hepatically Impaired Participants Versus Matched 
 Participants With Normal Hepatic Function\nEstimated primary completion: M
 ay 2027. This is a ClinicalTrials.gov estimate\, not a confirmed readout d
 ate\, and it can move.\nDrug page: https://assetmemo.bio/drug/casdatifan#u
 pcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07751
 250
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07227415-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20271102
DTEND;VALUE=DATE:20271103
SUMMARY:Casdatifan: Phase 1/2 readout est. (NCT07227415)
DESCRIPTION:Casdatifan\, phase 1/2\, Clear Cell Renal Cell Carcinoma.\nStud
 y: Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404
  Dosed Alone and in Combination With Other Anticancer Therapies in Adults 
 With Locally Advanced or Metastatic Renal Cell Cancer\nEstimated primary c
 ompletion: 2 November 2027. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/casdatifan#upcoming-events\nRegistry record: https://clinicaltrials
 .gov/study/NCT07227415
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07397611-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280131
DTEND;VALUE=DATE:20280201
SUMMARY:Casdatifan: Phase 2 readout est. (NCT07397611)
DESCRIPTION:Casdatifan\, phase 2.\nStudy: Pre-NEOSHIFT-RCC: Neoadjuvant HIF
 -Inhibitor Immunotherapy in RCC\nEstimated primary completion: 31 January 
 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/casdatifan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT07397611
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07011719-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20280430
DTEND;VALUE=DATE:20280501
SUMMARY:Casdatifan: Phase 3 readout est. (NCT07011719)
DESCRIPTION:Casdatifan\, phase 3\, Clear Cell Renal Cell Carcinoma.\nStudy:
  Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in P
 atients With Advanced Clear Cell Renal Cell Carcinoma\nEstimated primary c
 ompletion: April 2028. This is a ClinicalTrials.gov estimate\, not a confi
 rmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/dru
 g/casdatifan#upcoming-events\nRegistry record: https://clinicaltrials.gov/
 study/NCT07011719
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05536141-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20290331
DTEND;VALUE=DATE:20290401
SUMMARY:Casdatifan: Phase 1 readout est. (NCT05536141)
DESCRIPTION:Casdatifan\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStudy:
  A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal C
 ell Carcinoma and Other Solid Tumors\nEstimated primary completion: March 
 2029. This is a ClinicalTrials.gov estimate\, not a confirmed readout date
 \, and it can move.\nDrug page: https://assetmemo.bio/drug/casdatifan#upco
 ming-events\nRegistry record: https://clinicaltrials.gov/study/NCT05536141
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07293351-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20291128
DTEND;VALUE=DATE:20291129
SUMMARY:Casdatifan: Phase 1/2 readout est. (NCT07293351)
DESCRIPTION:Casdatifan\, phase 1/2.\nStudy: A Study to Evaluate the Safety\
 , Tolerability\, and Efficacy of Pumitamig Alone or in Combination With Ot
 her Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSET
 TA RCC-208)\nEstimated primary completion: 28 November 2029. This is a Cli
 nicalTrials.gov estimate\, not a confirmed readout date\, and it can move.
 \nDrug page: https://assetmemo.bio/drug/casdatifan#upcoming-events\nRegist
 ry record: https://clinicaltrials.gov/study/NCT07293351
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07748988-10820@assetmemo.bio
DTSTAMP:20261121T004026Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Casdatifan: Phase 1 readout est. (NCT07748988)
DESCRIPTION:Casdatifan\, phase 1\, Clear Cell Renal Cell Carcinoma.\nStudy:
  Casdatifan for the Treatment of Refractory Metastatic Clear Cell Renal Ce
 ll Carcinoma\nEstimated primary completion: 1 July 2030. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/casdatifan#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT07748988
URL:https://assetmemo.bio/drug/casdatifan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
